Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Goodwill (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Goodwill for 4 consecutive years, with $12.0 million as the latest value for Q4 2025.

  • Quarterly Goodwill changed 0.35% to $12.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Dec 2025, changed 0.35% year-over-year, with the annual reading at $12.0 million for FY2025, 0.35% changed from the prior year.
  • Goodwill hit $12.0 million in Q4 2025 for Axsome Therapeutics, roughly flat from $12.0 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $12.0 million in Q2 2023 to a low of $10.3 million in Q4 2022.
  • Historically, Goodwill has averaged $11.8 million across 4 years, with a median of $12.0 million in 2023.
  • Biggest YoY gain for Goodwill was 16.8% in 2024; the steepest drop was 0.35% in 2024.
  • Year by year, Goodwill stood at $10.3 million in 2022, then grew by 16.39% to $12.0 million in 2023, then increased by 0.35% to $12.0 million in 2024, then fell by 0.35% to $12.0 million in 2025.
  • Business Quant data shows Goodwill for AXSM at $12.0 million in Q4 2025, $12.0 million in Q3 2025, and $12.0 million in Q2 2025.